Added to YB: 2025-10-09
Pitch date: 2025-10-07
VLA.PA [bullish]
Valneva SE
-20.6%
current return
Author Info
Lux Opes Research covers European companies. Lots of them. Sign up for the newsletter.
Company Info
Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs.
Market Cap
EUR 836.3M
Pitch Price
EUR 4.70
Price Target
N/A
Dividend
N/A
EV/EBITDA
-27.68
P/E
-11.46
EV/Sales
4.44
Sector
Biotechnology
Category
turnaround
Valneva (VLA France): Reshaping its foundations
VLA.PA (quick overview): Biotech solved debt pressure via refinancing, extending timeline into next decade. Focus shifts to execution with Lyme vaccine (w/ Pfizer) data H1 2026, plus Zika/shigellosis pipeline. Financial clarity aligned with scientific progress heading into 2026.
Read full article (1 min)